Drug Trial Radar · NCT01364675
Primary Prevention of Cardiovascular Disease (CVD) in Pre-diabetic & Pre-hypertensive Subjects
Last checked: Nov 19, 2026Latest source record: Jun 2, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
8,900
Planned (sponsor's estimate)
Start
Jan 2012
Primary completion
Jul 2016
Study completion Dec 2016
Sponsor
- Lead sponsor
- Ramathibodi HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ubon Ratchathani Public Health Office, Thailand; National Health Security Office, Thailand; The Government Pharmaceutical Organization
- First posted
- Jun 2, 2011
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether treating pre-diabetic \& pre-hypertensive individuals using multiple drugs intervention (anti-hypertensive drugs (i.e., ACEI) plus anti-glycemic drug (i.e., metformin) plus anti-hyperlipidemic drug (statin)) would lower Cardiovascular Disease (CVD) events.
Conditions
- Pre-diabetes
- Pre-hypertension
Interventions
Metformin+Enalapril+SimvastatinDrug
Poly-pill - composed of Metformin (500 mg), Enalapril (10 mg) and Simvastatin (10 mg) in single tablet given once daily after dinner for 4 years
Placebo tabletDrug
Identical Placebo Tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cardiovascular EventsTime frame: 4-year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ubon ratchathani Public Health Office
Muang District, Changwat Ubon Ratchathani, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.